×
Luteal Phase Administration of Paroxetine for the Treatment of Premenstrual Dysphoric Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial in Canadian Women PDF
$ 40.00
Luteal Phase Administration of Paroxetine for the Treatment of Premenstrual Dysphoric Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial in Canadian Women PDF quantity
$ 40.00
×
The Child Behavior Checklist-Pediatric Bipolar Disorder Profile Predicts a Subsequent Diagnosis of Bipolar Disorder and Associated Impairments in ADHD Youth Growing Up: A Longitudinal Analysis PDF
$ 40.00
The Child Behavior Checklist-Pediatric Bipolar Disorder Profile Predicts a Subsequent Diagnosis of Bipolar Disorder and Associated Impairments in ADHD Youth Growing Up: A Longitudinal Analysis PDF quantity
$ 40.00
×
Women Are at Greater Risk of OCD Than Men: A Meta-Analytic Review of OCD Prevalence Worldwide PDF
$ 40.00
Women Are at Greater Risk of OCD Than Men: A Meta-Analytic Review of OCD Prevalence Worldwide PDF quantity
$ 40.00
×
Efficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Panic Disorder PDF
$ 40.00
Efficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Panic Disorder PDF quantity
$ 40.00
×
Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort PDF
$ 40.00
Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort PDF quantity
$ 40.00
×
The Retinoid X Receptor Agonist Bexarotene Relieves Positive Symptoms of Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial PDF
$ 40.00
The Retinoid X Receptor Agonist Bexarotene Relieves Positive Symptoms of Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial PDF quantity
$ 40.00
Coupon: Apply coupon
Update cart
